SHANGHAI, China – April 9, 2013 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced a new collaboration with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China. Through sharing knowledge, expertise and innovative capabilities, the two organizations will establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.
Special guests including key governmental leaders, Mr. Jianjun Cheng, CCP Secretary of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Mr. Weihua Song, Deputy Director of Shanghai Zhangjiang INNOPARK Administrative Committee; Mr. Robert Friel, PerkinElmer's Chairman and Chief Executive Officer; and Dr. Ming-Wei Wang, Director of NCDS among others, participated in a ceremony today celebrating the collaboration at the Chinese National Compound Library in Zhangjiang Hi-tech Park, Shanghai.
"It is an honor for PerkinElmer to collaborate with Dr. Wang, who is one of the pioneers in the field of personalized medicine," Mr. Friel said. "We look forward to working with Dr. Wang, the National Center for Drug Screening and Chinese scientists to develop a significant personalized drug research and development technology platform which will enable patients to be treated more accurately, safely, and efficiently."
The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions. As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations through utilizing next generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.
"As an important customer and long-term collaborator of PerkinElmer in the field of life sciences and drug discovery, the National Center for Drug Screening is committed to the research and development of new and effective drugs," Dr. Ming-Wei Wang said, "For the majority of drugs that are available in China, the respective biomarkers have not yet been fully validated. We are very excited to build this state-of-the-art personalized medicine program with PerkinElmer which will allow us to offer vital insights to improve the quality of healthcare in China."
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About The National Center for Drug Screening
The National Center for Drug Screening was jointly invested by the Ministry of Science and Technology, the Chinese Academy of Sciences and the Shanghai Municipality Government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, the Center offers drug screening services and technical consultation to universities, research institutions and pharmaceutical companies nationwide. For further information please visit www.screen.org.cn and www.cncl.org.cn.
PerkinElmer Inc. is a global leading company dedicating to improve human and environmental health and safety. The company's reported revenue in 2012 is about $2.1 billion. It has approximately 7,500 employees serving customers from more than 150 countries and regions and is ranked in the S&P 500 Index. For more information, please call 1-877-PKI-NYSE or visit www.perkinelmer.com.
# # #
Sophia Wang, PerkinElmer, Inc.
(86-021) 60645776 firstname.lastname@example.org
Josie Qiao (on behalf of PerkinElmer)
Text 100 Shanghai (86 -21) 61155266 ext. 892 Josie.email@example.com